Roche Holding AG (RHHBY) Stock Price & Analysis
Roche Holding AG (RHHBY) is trading at USD 60.68, up 1.78% today, as of October 23, 2026 at 16:26 UTC (US market open; quotes may be delayed), according to Nexqual market data.
RHHBY last closed at USD 59.62; today's session has ranged USD 59–61.45 on volume of 223,566 shares. Market capitalization is $386.78B, with a 52-week range of USD 40.07–61.45 (OQX). Source: Nexqual, retrieved October 23, 2026 at 16:41 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RHHBY.md
Key facts (RHHBY)
- Analysts: Hold (mean 2.50 on a 1–5 scale) (8 analysts), mean target USD 60.01 (range 52–67.1).
- Total return with dividends: 1Y +47.4% vs S&P 500 +14.6%; 5Y +48.6% vs S&P 500 +77.3%.
Analysts (RHHBY)
Consensus Hold (mean 2.50 on a 1–5 scale), 8 analysts; mean target USD 60.01 (low 52, high 67.1).
Total return (dividends reinvested) (RHHBY)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +47.4% | +48.6% |
| S&P 500 (SPY) | +14.6% | +77.3% |
| Per year | +47.4% | +8.3% |
| Volatility (annualized) | 28.3% | 24.5% |
| Max drawdown | -19.3% (Feb 2026→Mar 2026) | -39.6% (Apr 2022→Apr 2024) |
RHHBY analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | — | — | — | $15.73B | — |
| Next quarter (ends Dec 2026) | — | — | — | $16.60B | — |
| Current fiscal year (ends Dec 2026) | $3.10 | $3.07 | +0.9% | $63.01B | 5 |
| Next fiscal year (ends Dec 2027) | $3.33 | $3.38 | -1.3% | $66.09B | 5 |
Key Statistics (as of October 23, 2026 at 16:41 UTC)
| Price | USD 60.68 |
|---|---|
| Change | ▲ 1.78% (up) |
| Previous Close | USD 59.62 |
| Open | USD 59.48 |
| Day Range | USD 59 – 61.45 |
| 52-Week Range | USD 40.07 – 61.45 |
| Volume | 223,566 shares |
| Market Cap | $386.78B |
| Exchange | OQX |
Technical Analysis (RHHBY)
Nexqual's technical model rates RHHBY "BUY" based on 5 bullish and 3 bearish signals across 128 daily candles, as of October 23, 2026 at 16:41 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 78.24 (overbought) |
| vs SMA50 | Above (USD 55.15) |
| MACD | 1.42 (positive) |
Analyst Ratings (RHHBY)
Wall Street analysts rate RHHBY "Hold" based on 8 analysts, with a mean price target of USD 60.01 (range USD 52–67.1), per Nexqual as of October 23, 2026 at 16:41 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 60.01 |
| High Target | USD 67.1 |
| Low Target | USD 52 |
| Buy / Hold / Sell | 3 / 5 / 0 |
Earnings (RHHBY)
| Revenue Estimate | $15.73B |
|---|
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Financials & Fundamentals (RHHBY)
| Total Revenue | $62.96B |
|---|---|
| Revenue Growth (latest quarter, YoY) | -1.20% |
| Gross Margin | +74.17% |
| Operating Margin | +36.20% |
| Profit Margin | +19.60% |
| ROE | +38.11% |
| Debt / Equity | 0.91 |
| Current Ratio | 1.23 |
| Total Cash | $9.73B |
| Total Debt | $33.31B |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Financial Health Score (RHHBY)
Nexqual rates Roche Holding AG's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 16:41 UTC.
| Growth | Mixed — Revenue +1.7% YoY (annual), slow |
|---|---|
| Profitability | Strong — Gross margin 74%, operating 36% (last 12 months) |
| Balance Sheet | Mixed — CHF 9.73B cash vs CHF 33.3B debt |
| Cash Flow | Solid — Operating cash flow CHF 19.4B (TTM) |
| Efficiency | Strong — ROE 38%, ROA 13.5% |
Ownership (RHHBY)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.41% |
| Shares Outstanding | 5.52B |
| Float | 5.79B |
Source: Nexqual, October 23, 2026 at 16:41 UTC.
Leadership (RHHBY)
Roche Holding AG is led by Thomas Schinecker, Group Chief Executive Officer, per Nexqual as of October 23, 2026 at 16:41 UTC.
| Group Chief Executive Officer | Thomas Schinecker |
|---|---|
| Executive Chairman | Severin Schwan |
| Chief Financial Officer | Alan Hippe |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| MRK | Merck & Company, Inc. | USD 144.71 | ▼ 1.72% |
| ABBV | AbbVie Inc. | USD 285.38 | ▲ 0.06% |
| NVS | Novartis AG | USD 151.48 | ▼ 3.07% |
| AZN | AstraZeneca PLC | USD 171.6 | ▼ 0.56% |
| AMGN | Amgen Inc. | USD 442.16 | ▼ 1.14% |
| JNJ | Johnson & Johnson | USD 263.26 | ▼ 1.63% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 16:41 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt